Related Experiment Video
Updated: May 4, 2026

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols
Published on: June 6, 2017
MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27
1School of Public Health, Nantong University, Nantong, People's Republic of China.
Abstract:
The CDK inhibitor p27(kip1) plays crucial roles in cell cycle regulation and cancer progression. Through yeast two-hybrid screening, we identified MIF4G domain containing protein (MIF4GD) as a novel binding partner for p27. The association of MIF4GD and p27 was verified using immunoprecipitation and glutathione S-transferase (GST) pull-down assays. Interaction with MIF4GD led to the stabilization of p27 both in the nucleus and in the cytoplasm in hepatocellular carcinoma (HCC) cells as a result of suppressed phosphorylation of p27 by CDK2 at threonine187. Serum stimulation decreased the levels of MIF4GD and p27 simultaneously. In addition, MIF4GD overexpression resulted in increased p27 levels and reduced cell proliferation, while knockdown of MIF4GD promoted cell cycle progression with decreased p27 levels in cells. Furthermore, overexpression of MIF4GD reduced colony formation and inhibited xenograft tumor growth in nude mice. Finally, we found that both MIF4GD and p27 were expressed at low levels in HCC tissues compared to non-cancerous tissues, and that low expression levels of MIF4GD and p27 were associated with significantly worse prognosis in HCC patients. Our results suggest that MIF4GD is a potential regulator of p27-dependent cell proliferation in HCC. These findings provide a rational framework for the development of potential HCC therapy by targeting the MIF4GD-p27 interaction.
Insights
MIF4G domain containing protein (MIF4GD) stabilizes the cell cycle regulator p27, inhibiting hepatocellular carcinoma (HCC) cell proliferation and tumor growth. Low MIF4GD and p27 levels predict poor HCC prognosis.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Cycle Regulation
Background:
- The cyclin-dependent kinase (CDK) inhibitor p27(kip1) is vital for cell cycle control and cancer development.
- Identifying novel regulators of p27 is crucial for understanding and treating hepatocellular carcinoma (HCC).
Purpose of the Study:
- To identify novel binding partners of p27.
- To investigate the functional role of MIF4G domain containing protein (MIF4GD) in p27 regulation and HCC progression.
Main Methods:
- Yeast two-hybrid screening to identify p27 interacting proteins.
- Immunoprecipitation and GST pull-down assays to confirm protein interactions.
- Cellular assays (proliferation, cell cycle analysis), in vivo xenograft models, and analysis of clinical HCC tissues.
Main Results:
- MIF4GD was identified as a novel binding partner of p27.
- MIF4GD binding stabilizes p27 by inhibiting CDK2-mediated phosphorylation, reducing HCC cell proliferation and tumor growth.
- Low expression of MIF4GD and p27 correlates with poor prognosis in HCC patients.
Conclusions:
- MIF4GD acts as a novel regulator of p27 stability and function in HCC.
- The MIF4GD-p27 interaction represents a potential therapeutic target for HCC treatment.
- MIF4GD and p27 expression levels can serve as prognostic biomarkers for HCC.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Negative Regulator Molecules
Abnormal Proliferation
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis

